|
Company |
QMan |
Rank |
FS |
Rank |
QG&S |
Rank |
AAT |
Rank |
VLTI |
Rank |
CI |
Rank |
QMar |
Rank |
C&ER |
Rank |
UCA |
Rank |
TOTAL |
Rank |
| 1 |
Abbott (UK) |
6.5 |
3 |
7.5 |
3 |
7.5 |
3 |
6.5 |
5 |
6 |
3 |
6.5 |
2 |
7 |
2 |
5 |
5 |
6.5 |
2 |
59 |
3 |
| 2 |
AstraZeneca |
5.9 |
7 |
7.3 |
4 |
7.5 |
3 |
6.6 |
4 |
4.9 |
10 |
5 |
7 |
6.8 |
4 |
6 |
2 |
6.5 |
2 |
56.4 |
5 |
| 3 |
GlaxoSmithKline (GSK) |
7.6 |
2 |
8.4 |
1 |
7 |
6 |
7.6 |
1 |
6 |
3 |
6 |
4 |
7.9 |
1 |
6.5 |
1 |
6.5 |
2 |
63.5 |
1 |
| 4 |
Hikma Pharmaceuticals |
4.7 |
10 |
3.7 |
10 |
4.3 |
10 |
2.3 |
10 |
5 |
9 |
1.3 |
10 |
4.3 |
10 |
3.3 |
10 |
3.3 |
10 |
32.3 |
10 |
| 5 |
Lilly (Eli) UK |
6 |
4 |
6 |
8 |
7 |
6 |
6 |
8 |
5.3 |
6 |
5.3 |
6 |
5 |
9 |
4.7 |
8 |
4.3 |
9 |
49.7 |
9 |
| 6 |
Novo-Nordisk AS UK |
5.7 |
9 |
6.7 |
6 |
7.7 |
2 |
6.3 |
7 |
6.7 |
2 |
6 |
4 |
5.3 |
7 |
4.7 |
8 |
5.7 |
7 |
54.7 |
6 |
| 7 |
Pfizer (UK) |
6 |
4 |
7 |
5 |
6.5 |
8 |
7.5 |
2 |
5.3 |
8 |
4.8 |
8 |
5.3 |
8 |
5.8 |
3 |
4.8 |
8 |
52.8 |
7 |
| 8 |
Reckitt Benckiser |
7.7 |
1 |
7.7 |
2 |
7.3 |
5 |
7 |
3 |
6 |
3 |
7 |
1 |
7 |
2 |
5 |
5 |
6.7 |
1 |
61.3 |
2 |
| 9 |
Shire |
6 |
4 |
6 |
8 |
6 |
9 |
5.3 |
9 |
5.3 |
6 |
3.6 |
9 |
6.5 |
5 |
4.8 |
7 |
6.3 |
5 |
49.9 |
8 |
| 10 |
Smith & Nephew |
5.8 |
8 |
6.6 |
7 |
7.7 |
1 |
6.5 |
5 |
7.6 |
1 |
6.3 |
3 |
6.1 |
6 |
5.4 |
4 |
6.3 |
6 |
58.2 |
4 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
537.7 |
|
QMan = Quality of Management, FS = Financial Soundness, QG&S = Quality of Goods & Services, AAT = Ability to Attract, Develop and Retain Top Talent,
VLTI = Value as a Long Term Investment, CI = Capacity to Innovate, Q Mar = Quality of Marketing, C&ER = Community and Environmental Responsibility,
UCA = Use of Corporate Assets |
|
